Genmab A/S: Circling Back On This Complicated Story [Seeking Alpha]
Genmab A/S - American Depositary Shares (GMAB)
Company Research
Source: Seeking Alpha
Investing Group Leader Follow Summary Genmab A/S shares have dropped just over 25% since May 2024 due to setbacks, despite positive data from Epkinly and a shift to a more expensive operational model. The recent acquisition of ProfoundBio added key clinical programs and ADC technology, enhancing Genmab's antibody platforms and pipeline. Despite increased revenue and an upward earnings outlook, concerns over setbacks and a lower operating margin have led to mixed analyst ratings and stock price compression. An updated analysis of GMAB stock follows in the paragraphs below. Looking for a helping hand in the market? Members of The Biotech Forum get exclusive ideas and guidance to navigate any climate. Learn More » Bill Oxford Shares of Danish antibody concern Genmab A/S ( GMAB have lost more than 25% since our last look at the stock in early May of this year, as two minor setbacks and hand-wringing regarding a potential third one Live Chat on The Biotech Forum has be
Show less
Read more
Impact Snapshot
Event Time:
GMAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GMAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GMAB alerts
High impacting Genmab A/S - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
GMAB
News
- Genmab A/S (NASDAQ: GMAB) was upgraded by analysts at Sanford C. Bernstein from a "strong sell" rating to a "hold" rating.MarketBeat
- Antibody Discovery Market Industry Forecast Report 2024-2035, Featuring Ablexis, ChemPartner, Creative Biolabs, GenScript, Genmab, Harbour BioMed, MabSilico, Nona Biosciences, WuXi Biologics and More [Yahoo! Finance]Yahoo! Finance
- FairJourney Biologics Establishes Scientific Advisory Board [Yahoo! Finance]Yahoo! Finance
- Genmab to Hold 2024 R&D Update and ASH Data Review Meeting [Yahoo! Finance]Yahoo! Finance
- City of Hope Reports Novel Immunotherapy in Clinical Trial Shows Promise for Patients With Relapsed or Difficult to Treat Chronic Lymphocytic Leukemia (CLL) [Yahoo! Finance]Yahoo! Finance